Amylyx Pharmaceuticals, Inc. Restructuring Charges
Amylyx Pharmaceuticals, Inc. (AMLX) reported Restructuring Charges of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. restructuring charges for the quarter ending 2025-12-31 was $0.00.
- Amylyx Pharmaceuticals, Inc. restructuring charges for the quarter ending 2025-09-30 was $0.00.
- Amylyx Pharmaceuticals, Inc. restructuring charges for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. restructuring charges for the quarter ending 2025-03-31 was $0.00.
- Amylyx Pharmaceuticals, Inc. restructuring charges for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. restructuring charges for fiscal 2024 was $22.85M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $22.85M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $22.85M derived: sum of 3 quarters · filed 2026-03-03 | $22.85M 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $22.85M derived: sum of 2 quarters · filed 2025-11-06 | $22.85M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $22.85M 10-Q · filed 2025-08-07 | $22.85M 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |